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Abstract
Objective-Ocular myasthenia gravis is a subtype of myasthenia gravis that causes relatively mild disability, but may convert into severe generalised muscle weakness. A universal management plan for ocular myasthenia gravis has not been established. This study was performed to determine the outcome of ocular myasthenia gravis with the currently available therapeutic options. Methods-Retrospective analysis of 78 patients with ocular myasthenia gravis with a mean disease duration of (range 0 5-58-3) years. Results-In 54 patients (69%) symptoms and signs remained confined to the extraocular muscles during the observation period. The remaining 24 patients (31%) developed symptoms of generalised myasthenia gravis; 50% of them within two years, 75% within four years after onset. A somewhat reduced risk of generalisation was found in those with mild symptoms, normal repetitive nerve stimulation test, and low or absent antiacetylcholine receptor (AChR) antibodies at the time of diagnosis. Patients receiving immunosuppressive treatment (corticosteroids and/or azathioprine) rarely developed generalised myasthenia gravis (six of 50, 12%). Those without such treatment, usually due to uncertain diagnosis and late referral, converted into generalised myasthenia gravis significantly more often (18 of 28, 64%). Conclusions-The prognosis of ocular myasthenia gravis is good. A conventional scheme with short term corticosteroids and long term azathioprine seems adequate to achieve remission in most patients. The Myasthenia gravis is one of the best studied autoimmune diseases and the remarkable progress in understanding the underlying aetiology and pathogenetic heterogeneity has helped to improve patient management. According to age of onset, thymic abnormalities, and other immune variables patients with generalised myasthenia gravis can be divided into three main groups: (a) "young onset" patients (< 45 years, mainly female), who regularly have thymic hyperplasia; (b) "old onset" patients (> 45 years, slightly more men), who normally have thymic atrophy; and (c) the group of thymoma patients who have no clear age and sex bias.' 9 As not all patients with ocular muscle weakness fit into one of these categories, there is often uncertainty about the treatment options which are best in ocular myasthenia gravis. Particularly, there is no clearcut guideline as to the need for thymectomy, mostly performed in groups (a) and (c), or long term immunosuppression, which may be beneficial for all three patient groups with generalised disease.
Apart from symptomatic treatment with anticholinesterase drugs, corticosteroids are regularly considered in all forms of myasthenia gravis, with good results in most patients. 10'2 The indications for immunosuppressive drugs, such as azathioprine, cyclophosphamide, or cyclosporine are less clear. Although these drugs have clearly been shown to be beneficial in generalised myasthenia gravis,613'415 some neurologists prefer to limit their application to the more severely affected patients.'6 Also, scepticism about the drug treatment is fostered by the fact that very few prospective double blind trials have been performed for any compound. 1'-15 Thymectomy is the generally accepted treatment for patients with thymoma and in young onset patients. This is based on immunological evidence that thymic changes play a central part in the pathogenesis of myasthenia gravis, at least in these two patient groups. '7-19 Uncertainty, however, exists as to the value of thymectomy in older patients with thymic atrophy, patients with generalised myasthenia gravis that are negative for serum AchR antibodies, and also in purely ocular 2 20 21 myasthenia gravis.
In this study, we have reviewed patients with purely ocular muscle weakness.
Patients and methods All patients included in this study were examined in our myasthenia clinic between January 1989 and April 1993 at least twice a year by one of us (NS or AM). In patients with a longer history previous hospital charts were reviewed. In a few patients additional follow up data were collected from referring neurologists.
The diagnosis of ocular myasthenia gravis was based on conventional clinical and laboratory criteria. 1 2 7 If AChR antibodies and repetitive nerve stimulation were both negative, then clinical signs, edrophonium chloride (Tensilon) testing, and treatment response, as well as other diagnostic measures (normal CT or MRI and CSF investigation) were re-evaluated carefully to exclude other causes of eye muscle weakness (see also comment on differential diagnosis below). Because of its low specificity, a positive edrophonium chloride test was never used as a single diagnostic criterion. [22] [23] [24] [25] Patients were only included if symptoms and signs were restricted to the extraocular muscles for at least three months after onset. This arbitrary limit seemed reasonable, because early disease stages (often before referral) were usually not well documented. Also, we thought that the development of generalised myasthenia gravis after a few days or weeks of exclusive weakness of extraocular muscles would not qualify for a diagnosis of ocular myasthenia gravis as a separate entity. In this respect we follow the criteria of Oosterhuis.'6 Also, subtle signs of generalised weakness, particularly facial weakness, were sought for and, if present, those patients were not included. Grading of severity of disease was semiquantive. "Mild", "moderate", or "severe" ocular myasthenia gravis stands for mild, moderate, or severe disability in everyday life, with particular respect to impairment at work and car driving. This seemed more appropriate as the clinically more relevant subjective impairment does not necessarily correlate with the actual degree of extraocular muscle weakness. Improvement was documented when ocular myasthenia gravis was ameliorated by at least one such grade. Remission was stated when there was no remaining disability with or without drug treatment.
Repetitive nerve stimulation was performed according to Schumm and St6hr27 with minor modifications.The accessory nerve was stimulated behind the sternocleidomastoid muscle with supramaximal intensity at 3 Hz with a bipolar surface electrode and recorded from the trapezius muscle. A decrement of greater than 10% between the first and fifth potential was considered pathological.
Antibodies to AChRs were measured by radioimmunoassay according to Vincent and Newsom-Davis.'8 Human amputated leg muscle was used as a source of antigen, incubated with 12'I-a-bungarotoxin (Amersham-Buchler, Brunswick, Germany) and subsequently with different dilutions of the patients' serum. After thorough washing the bound radioactivity was measured on a 1counter. Known negative, positive, and equivocal serum samples were run in each assay. Values greater than 05 nmol a-bungarotoxin binding sites/l were considered positive, between 0-2 and 0 5 nmol/l equivocal, and less than 0-2 nmol/l negative. To avoid variations between assays, follow up investigations always included retesting of the previous one or two serum samples of a patient together with the new serum.
Results

PATIENTS
We had clinical data from 178 patients with myasthenia gravis; 78 of them (44%; 40 female, 38 male) were diagnosed to have ocular myasthenia gravis according to the criteria outlined above. Mean duration of disease was 8 years 4 months (SD 9 years, range 6 months-58 years 2 months). Twenty four of the 78 patients with ocular myasthenia gravis (31%, 13 female, 11 male) developed symptoms of generalised muscle weakness later during the course (see below). Age and sex distribution of ocular, primary, or secondary generalised patients were not significantly different (age at onset for all 78 patients with ocular myasthenia gravis: mean 50-6 (SD 19-5) years, range 10-84 years; data not shown). Remarkably, the diagnosis of myasthenia gravis in the 78 ocular patients was made only 39-8 (SD 93-5) months after the onset of symptoms.
Concomitant autoimmune diseases were diagnosed in 39 (22%) of all 178 patients with myasthenia gravis reviewed in this study. Thyroid disease was by far the most common condition (33 patients, 19%; female:male ratio 3-1:1). These proportions were not significantly different among the ocular patients (for example, total incidence of thyroid disease 19 of 78, 24%).
Family history disclosed that six of the 178 patients (3%) had a first or second degree relative with myasthenia gravis. Two pairs of siblings (including one pair of monozygotic twins) had generalised myasthenia gravis; another two in the ocular group had relatives with generalised myasthenia gravis who were not part of our sample.
DIFFERENTIAL DIAGNOSIS OF SERONEGATIVE OCULAR MYASTHENIA GRAVIS
In three female patients (ages 45, 57, and 74 years) referred to us with suspected seronega-tive ocular myasthenia gravis, this diagnosis had to be revised during the course. All three had double vision and unilateral ptosis with mild daily fluctuations and the diagnosis had mainly been based on a positive edrophonium chloride test. AChR-antibodies and electrophysiology were normal. One of the patients had been thymectomised and thymic remnants without germinal centres were found. When re-evaluating the diagnosis, we found unilateral contrast enhancing lesions on CT and MRI in the region of the cavernous sinus in all three. These patients are not included in the present evaluation, but deserve mention, because their history reflects well the diagnostic problems encountered in ocular myasthenia gravis. The MRI of one of the patients has been published previously.7 PROGNOSTIC FACTORS Using secondary generalisation as an end point, no significant prognostic factor could be determined. Nevertheless, mild symptoms at onset, normal results at repetitive nerve stimulation, and negative serum AchR antibody testing were found more often in patients whose myasthenia remained limited to extraocular muscles (fig lA-C Patients with a pathological decrement in repetitive accessory nerve stimulation converted to generalised myasthenia gravis in 32% (six of 19), but only 15% (seven of 47) did so with an initially normal electrophysiological result (x2 = 2-38, NS; fig iB) .
Among the seronegative patients one of 23 (4%) developed generalised myasthenia gravis. This proportion was significantly higher in the seropositive group (11 of 43, 26%; X2 = 4 54, P < 005; fig 1C) . Also, in patients with secondary generalisation the mean antibody titre was significantly higher at the first diagnostic testing (mean 11 9 (SD 14-4), range 0-47-5 nmol/l) than in the permanently ocular patients (mean 4 1 (SD 6-0), range 0-25 9 nmol/l; t = 3-02, P < 0-01; not shown). As expected, the maximum levels during the whole observation period were tenfold higher in the patients with generalisation (61-6 (SD 116-7) nmol/l) compared with those who remained ocular (6-3 (SD 13-7) nmol/l).
Tensilon testing was positive in 97% of the patients with ocular myasthenia gravis, but was never used as a single diagnostic criterion (see above).
Data on HIA were available in 21 out of the 78 of the ocular patients and there was detectable trend towards a specific association; further investigation was not performed. Time (months) 
Discussion
Ocular myasthenia gravis had a good prognosis in most patients in this study. In 69% the disease remained confined to the extraocular muscles. Of these, 54% were in remission, 33% improved, and 13% patients were unchanged at the end of the study. The most remarkable difference from previous studies is the relatively low fraction of patients converting to generalised myasthenia gravis, which was 31% in our population, but 49-69% in other previous reports. The development of generalised symptoms was used as a major end point by us and others, because it indicates major progression of disease and management has to be re-evaluated. In the study published in 1983 by Bever et al29 53 of 108 patients (diagnosed 1957-69 in New York City)-that is, 49%-later generalised. Grob reported in his large collective30 that about 40%, and in a later survey3l 34% of 202, of his patients with initial ocular myasthe-nia gravis would remain ocular. The authors of those studies do not report details on possible immunosuppressive treatments applied to patients with ocular myasthenia gravis. As both series started decades ago it might safely be assumed that only a small proportion of patients had corticosteroids and even fewer had azathioprine.
Oosterhuis reviewed an even earlier series of patients who were first documented between 1926 and 1965 in Amsterdam and had to be managed without steroid or other immunosuppressive treatment. 26 In this group 24 of 35 (69%) developed generalised myasthenia gravis, probably most realistically reflecting the natural course of the disease. Although patient groups in the various studies may not be comparable with each other, it is evident that there is a gradual evolution towards a lower proportion with secondary generalisation. Common to all studies, including ours, is the finding that the risk of generalisation is greatest soon after onset, gradually declining with time. Of the patients developing generalised myasthenia gravis 50% did so by two years after onset in our study, 88% in Oosterhuis' group,26 83% in the study of Bever et al. 29 The proportion of 64% seropositive patients in our group was comparable with most of the previously published results (45%-71%).28 32 30 Whereas diagnosis of ocular myasthenia gravis is straightforward in a patient with a compatible history and detectable serum AchR antibodies, diagnostic problems arise in the seronegative patients. Suspicion should be aroused especially if extraocular muscle weakness is unilateral and follows a neurogenic pattern 
